Literature DB >> 9874263

Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells.

V Jérôme1, R Müller.   

Abstract

A major challenge in the gene therapy of proliferative diseases is the specific targeting of gene expression. Here we describe a new approach based on the development of dual-specificity promoters that are both cell type specific and cell cycle regulated. The gene of interest is driven by an artificial heterodimeric transcription factor, whose DNA-binding subunit is expressed from a tissue-specific promoter, whereas the trans-activating subunit is transcribed from a cell cycle-regulated promoter. As a result gene expression occurs preferentially in the proliferating cells of a specific type of tissue. The selectivity of this strategy is demonstrated for the expression of a transgene in proliferating melanoma cells, using a combination of cyclin A and tyrosinase promoter elements. We also show that the level of expression that can be achieved by this system is sufficient to induce a clear biological effect in a TNF-alpha cytotoxicity assay.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874263     DOI: 10.1089/hum.1998.9.18-2653

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

1.  Transcriptional profiling identifies functional interactions of TGF β and PPAR β/δ signaling: synergistic induction of ANGPTL4 transcription.

Authors:  Kerstin Kaddatz; Till Adhikary; Florian Finkernagel; Wolfgang Meissner; Sabine Müller-Brüsselbach; Rolf Müller
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

2.  Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.

Authors:  Prajakta S Palkar; Michael G Borland; Simone Naruhn; Christina H Ferry; Christina Lee; Ugir H Sk; Arun K Sharma; Shantu Amin; Iain A Murray; Cherie R Anderson; Gary H Perdew; Frank J Gonzalez; Rolf Müller; Jeffrey M Peters
Journal:  Mol Pharmacol       Date:  2010-06-01       Impact factor: 4.054

3.  A tunable dual-promoter integrator for targeting of cancer cells.

Authors:  Lior Nissim; Roy H Bar-Ziv
Journal:  Mol Syst Biol       Date:  2010-12-21       Impact factor: 11.429

4.  Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment.

Authors:  Tim Schumann; Till Adhikary; Annika Wortmann; Florian Finkernagel; Sonja Lieber; Evelyn Schnitzer; Nathalie Legrand; Yvonne Schober; W Andreas Nockher; Philipp M Toth; Wibke E Diederich; Andrea Nist; Thorsten Stiewe; Uwe Wagner; Silke Reinartz; Sabine Müller-Brüsselbach; Rolf Müller
Journal:  Oncotarget       Date:  2015-05-30

5.  A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system.

Authors:  Marina Sudomoina; Ekaterina Latypova; Olga O Favorova; Erica A Golemis; Ilya G Serebriiskii
Journal:  BMC Biotechnol       Date:  2004-04-29       Impact factor: 2.563

6.  Transcriptional Targeting in Cancer Gene Therapy.

Authors:  Tracy Robson; David G. Hirst
Journal:  J Biomed Biotechnol       Date:  2003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.